269 related articles for article (PubMed ID: 36151707)
1. Severe Pancytopenia After COVID-19 Revealing a Case of Primary Bone Marrow Diffuse Large B Cell Lymphoma.
Kilani Y; Sohail H; Lim CY; Payette A; Kamal SAF; Afzal A; Khan T; Paracha N; Muppidi MR; Sittler D
Am J Case Rep; 2022 Sep; 23():e937500. PubMed ID: 36151707
[TBL] [Abstract][Full Text] [Related]
2. Case Report Diffuse large B-cell lymphoma in the primary bone marrow.
Hu Y; Chen SL; Huang ZX; Gao W; An N
Genet Mol Res; 2015 Jun; 14(2):6247-50. PubMed ID: 26125825
[TBL] [Abstract][Full Text] [Related]
3. Predictive Parameters of Febrile Neutropenia and Clinical Significance of G-CSF Receptor Signaling Pathway in the Development of Neutropenia during R-CHOP Chemotherapy with Prophylactic Pegfilgrastim in Patients with Diffuse Large B-Cell Lymphoma.
Kim DY; Nam J; Chung JS; Jeon BE; Lee JH; Jo JC; Kim SW; Shin HJ
Cancer Res Treat; 2022 Oct; 54(4):1256-1267. PubMed ID: 34990523
[TBL] [Abstract][Full Text] [Related]
4. Composite B-cell and T-cell lymphomas: clinical, pathological, and molecular features of three cases and literature review.
Jin X; Liu H; Li J; Xiao X; Yuan X; Chen P; Chen B; Liang Y; Huang F
J Zhejiang Univ Sci B; 2023 Aug; 24(8):711-722. PubMed ID: 37551557
[TBL] [Abstract][Full Text] [Related]
5. Chidamide combined with ibrutinib improved the prognosis of primary bone marrow diffuse large B cell lymphoma.
Tian C; Chen Z; Li Y
J Int Med Res; 2020 Jul; 48(7):300060520936053. PubMed ID: 32643971
[TBL] [Abstract][Full Text] [Related]
6. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of bone marrow 2-[
Lim CH; Hyun SH; Cho YS; Choi JY; Lee KH
Clin Radiol; 2021 Jul; 76(7):550.e19-550.e28. PubMed ID: 33762136
[TBL] [Abstract][Full Text] [Related]
8. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
9. A rare case of diffuse large B-cell lymphoma-associated hemophagocytic lymphohistiocytosis.
Malkan UY; Albayrak M; Yildiz A; Maral S; Afacan Ozturk HB; Comert P
J Oncol Pharm Pract; 2021 Jan; 27(1):250-252. PubMed ID: 32507098
[TBL] [Abstract][Full Text] [Related]
10. Primary diffuse large B-cell lymphoma of the Larynx.
Higo R; Kojima M; Itoh S; Noguchi M; Izumi H; Takeuchi K
Auris Nasus Larynx; 2023 Aug; 50(4):632-636. PubMed ID: 35863932
[TBL] [Abstract][Full Text] [Related]
11. [Rituximab plus Autologous Hemotopoietic Stem Cell Transplantation for The Treatment of CD5 Positive Diffuse Large B Cell Lymphoma with Autoimmune Hemolytic Anemia].
Huang YQ; Zheng RJ; Wu RJ; Ma XD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Jun; 24(3):722-6. PubMed ID: 27342498
[TBL] [Abstract][Full Text] [Related]
12. [Rupture of hepatic lesion of diffuse large B-cell lymphoma following immunochemotherapy].
Segawa R; Natazuka T
Rinsho Ketsueki; 2022; 63(3):211-216. PubMed ID: 35387935
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic significance of tumor microenvironment CD11c, and FOXP3 expression in diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy.
Lee S; Kim DH; Oh SY; Kim SY; Koh MS; Lee JH; Lee S; Kim SH; Kwak JY; Pak MG; Ju MH; Kim HJ; Jeong JS
Korean J Intern Med; 2017 Mar; 32(2):335-344. PubMed ID: 26968188
[TBL] [Abstract][Full Text] [Related]
14. Clinical benefit of R-CHOP without splenectomy in stage I primary splenic diffuse large B-cell lymphoma.
Rajendran T; Kini JR; Abna A; Prasad K
BMJ Case Rep; 2022 Jan; 15(1):. PubMed ID: 34983812
[TBL] [Abstract][Full Text] [Related]
15. [Systemic chemotherapy combined with thrombopoietin receptor agonist for the treatment of diffuse large B-cell lymphoma complicated with aplastic anemia].
Fukuda Y; Edahiro Y; Takaku T; Furuya C; Shirane S; Hamano Y; Koike M; Komatsu N
Rinsho Ketsueki; 2022; 63(1):20-25. PubMed ID: 35135947
[TBL] [Abstract][Full Text] [Related]
16. Diffuse large B-cell lymphoma originating from the rectum and diagnosed after rectal perforation during the treatment of ulcerative colitis: a case report.
Suzuki T; Iwamoto K; Nozaki R; Saiki Y; Tanaka M; Fukunaga M; Yamada K
BMC Surg; 2021 Jan; 21(1):50. PubMed ID: 33478454
[TBL] [Abstract][Full Text] [Related]
17. Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies.
Purdum A; Tieu R; Reddy SR; Broder MS
Oncologist; 2019 Sep; 24(9):1229-1236. PubMed ID: 30850561
[TBL] [Abstract][Full Text] [Related]
18. Novel prognostic index based on hemoglobin level and platelet count for diffuse large B-cell lymphoma, not otherwise specified in the R-CHOP era.
Nakayama S; Matsuda M; Adachi T; Sueda S; Ohashi Y; Awaji S; Hashimoto S; Matsumura I
Platelets; 2019; 30(5):637-645. PubMed ID: 30047815
[TBL] [Abstract][Full Text] [Related]
19. Primary diffuse large B cell lymphoma (DLBCL) of the prostate presenting with lower urinary tract symptoms (LUTS).
Nusrat A; Nazim SM
BMJ Case Rep; 2020 Dec; 13(12):. PubMed ID: 33370963
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Go SI; Park MJ; Song HN; Kim HG; Kang MH; Lee HR; Kim Y; Kim RB; Lee SI; Lee GW
J Cachexia Sarcopenia Muscle; 2016 Dec; 7(5):567-576. PubMed ID: 27104110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
